Guilherme Garcia Barros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guilherme Garcia Barros has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Feldman
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication - Adam S. Kibel
Department of Urology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
1 shared publication Arnaldo Fazoli
1 shared publication- Bernard H. Bochner
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
1 shared publication - Christopher J. Magnani
Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts
1 shared publication - David B. Solit
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (9)
Clinical and Genomic Profiling of Early-Onset Bladder Cancer Identifies Key Alterations and Therapeutic Targets
Purpose: Younger patients with bladder cancer have fewer environmental exposures or risk factors, suggesting that the molecular pathways implicated in early-onset disease differ from older patients. Dissecting the genomic profiles of early-onset tumors may inform targeted treatment strategies for young patients. We compared the frequency of somatic mutations in early-onset bladder cancer, defined as a diagnosis before the age of 55 years, which encompasses the youngest patients in approximately 1 in 10 diagnoses based on national registries. Material and methods: We assessed 2 institutional cohorts: the Mass General Brigham Young Cystectomy Cohort (MGB-YCC, n = 134 patients) from 2008 to 2023 and the Memorial Sloan Kettering-IMPACT bladder cancer cohort (MSK-IMPACT, n = 1271 including n = 207 cystectomy and n = 811 transurethral resection (TUR) specimens) from 2014 to 2021. Clinical outcomes were compared with patients undergoing cystectomy in the National Surgical Quality Improvement Program (NSQIP, n = 10,848). Results: MGB-YCC and MSK-IMPACT cohorts were predominantly male (> 75%), and younger patients had lower rates of smoking history or muscle-invasive disease. MGB-YCC demonstrated more patients with continent diversions (51.5% vs 14.9%) than the older population in NSQIP, although complication rates were similar. Genomic characterization of MGB-YCC demonstrated enrichment in younger patients of TP53 (65% overall, 83% < 50-year- old, P = .045) and KMT2D mutations almost exclusively in the youngest patients (35% overall, 83% < 45-years-old, P = .008). MSK-IMPACT revealed a significant increase in FGFR3 mutations in younger patients in both cystectomy (33% vs 13%, P = .014) and TUR (45% vs 27%, P < .001). Conclusions: Our results indicate that early-onset bladder cancer is a distinct patient population that has disease driven by specific somatic mutations, some of which represent therapeutic targets. This suggests potential benefits of genomic tumor profiling in guiding personalized treatment.
- 1 September 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (9)
Open AccessClinical and Genomic Profiling of Early-Onset Bladder Cancer Identifies Key Alterations and Therapeutic Targets
Purpose: Younger patients with bladder cancer have fewer environmental exposures or risk factors, suggesting that the molecular pathways implicated in early-onset disease differ from older patients. Dissecting the genomic profiles of early-onset tumors may inform targeted treatment strategies for young patients. We compared the frequency of somatic mutations in early-onset bladder cancer, defined as a diagnosis before the age of 55 years, which encompasses the youngest patients in approximately 1 in 10 diagnoses based on national registries. Material and methods: We assessed 2 institutional cohorts: the Mass General Brigham Young Cystectomy Cohort (MGB-YCC, n = 134 patients) from 2008 to 2023 and the Memorial Sloan Kettering-IMPACT bladder cancer cohort (MSK-IMPACT, n = 1271 including n = 207 cystectomy and n = 811 transurethral resection (TUR) specimens) from 2014 to 2021. Clinical outcomes were compared with patients undergoing cystectomy in the National Surgical Quality Improvement Program (NSQIP, n = 10,848). Results: MGB-YCC and MSK-IMPACT cohorts were predominantly male (> 75%), and younger patients had lower rates of smoking history or muscle-invasive disease. MGB-YCC demonstrated more patients with continent diversions (51.5% vs 14.9%) than the older population in NSQIP, although complication rates were similar. Genomic characterization of MGB-YCC demonstrated enrichment in younger patients of TP53 (65% overall, 83% < 50-year- old, P = .045) and KMT2D mutations almost exclusively in the youngest patients (35% overall, 83% < 45-years-old, P = .008). MSK-IMPACT revealed a significant increase in FGFR3 mutations in younger patients in both cystectomy (33% vs 13%, P = .014) and TUR (45% vs 27%, P < .001). Conclusions: Our results indicate that early-onset bladder cancer is a distinct patient population that has disease driven by specific somatic mutations, some of which represent therapeutic targets. This suggests potential benefits of genomic tumor profiling in guiding personalized treatment.
- Open Access
- 2 August 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (7)
Nomograms for Predicting Recurrence and Oncologic Outcomes After Partial Nephrectomy for Renal Cell Carcinoma
- 2 August 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (7)
Open AccessNomograms for Predicting Recurrence and Oncologic Outcomes After Partial Nephrectomy for Renal Cell Carcinoma
- Open Access
- 8 July 2026
- Published by Elsevier in Urology Video Journal
- Vol. 31
Robot-assisted segmental ureterectomy and primary ureteropelvic anastomosis for upper tract urothelial carcinoma
- 8 July 2026
- Published by Elsevier in Urology Video Journal
- Vol. 31
Open AccessRobot-assisted segmental ureterectomy and primary ureteropelvic anastomosis for upper tract urothelial carcinoma
- Open Access
- 1 May 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (5)
Editorial Comment: Prostate Cancer Survivors' Long-Term Supportive Care Needs: Results From a Population-Based Cohort
- 1 May 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (5)
Open AccessEditorial Comment: Prostate Cancer Survivors' Long-Term Supportive Care Needs: Results From a Population-Based Cohort